Breaking the resistance barrier: synergistic evolution of CAR-T cells and bispecific antibodies in the era of precision immuno-oncology.

Front Immunol · 2026 · PMC13365049 · PMID 42454036

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Similarly, the TRANSFORM study reported a highly significant elongation of median EFS favoring the early CAR-T arm (10.1 months vs. 2.3 months; HR: 0.35), establishing that early cellular deployment significantly thwarts clonal evolution before the tumor acquires resistant sub-clonal variants ( 18 ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.